Pasithea Therapeutics Corp. (NASDAQ:KTTA – Get Free Report) traded down 16.9% on Monday . The company traded as low as $1.13 and last traded at $1.18. 634,853 shares were traded during mid-day trading, a decline of 34% from the average session volume of 960,275 shares. The stock had previously closed at $1.42.
Pasithea Therapeutics Stock Up 3.8 %
The stock has a market cap of $3.71 million, a P/E ratio of -0.11 and a beta of 0.59. The firm’s 50 day simple moving average is $1.25 and its two-hundred day simple moving average is $2.56.
Pasithea Therapeutics (NASDAQ:KTTA – Get Free Report) last issued its quarterly earnings data on Monday, March 24th. The company reported ($2.41) earnings per share (EPS) for the quarter.
About Pasithea Therapeutics
Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.
Read More
- Five stocks we like better than Pasithea Therapeutics
- How to Use the MarketBeat Excel Dividend Calculator
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- 3 Stocks to Consider Buying in October
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- How to Calculate Stock Profit
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for Pasithea Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pasithea Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
